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Introduction 
Genetic variants 
Multidrug resistance: 
• Many tumors show initial resistance to chemotherapy or acquired in the course of 
treatment, which is the major obstacle in curing these cases.  
• Chemotherapy is widely used as a treatment modality in oncology, but their 
effectiveness has been limited due to the existence of multidrug resistance. 
• Although there are several genes involved in this phenomenon, one of the most 
important genes in pharmacogenetics and chemotherapy is MDR1 gene because 
many drugs used as antitumor agents are substrates for P-Glycoprotein (P-gp), 
MDR1 encoded protein.  
General goals:  
• Develop a bibliographical research about MDR1 gene, involved in multiresistance 
phenomenon, and polymorphisms that generate variations in response to 
chemotherapy. 
Specific goals:  
• Determine the structure and clinically relevant substrates of P-glycoprotein (P-gp). 
• Determine the polymorphisms that have been identified in the coding sequence of 
MDR1 gene. 
• Relate the presence of the most studied polymorphisms with the expression and 
function pf P-gp, and his clinical behavior en patients with leukemia, specifically in acute 
lymphocytic leukemia (ALL). 
• Identify an additional treatment for leukemia that avoids multiresistance and toxicity. 
  P-glycoprotein: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• ATP-dependent efflux pump with broad substrate specificity that is 
capable of removing cytotoxic agents from inside the cell, allowing 
resistance to chemotherapy.
SNPs associated with altered P-gp functionality and expression: 
• Genetic variations affect the interindividual variability of drug pharmacokinetics.  
For that reason, MDR1 has been extensively studied, with at least 50 SNPs identified 
How C3435T polymorphism affects P-gp? 
• Could be linked to another 
polymorphism? 
1236TT/2677TT/3435TT 
haplotype 
Changes in the 
conformation of the 
binding sites of P-gp 
Conclusion 
• The final phenotype is defined by the whole drug efflux transporters, 
in conjunction with metabolism enzymes like CYPs. 
Identified problems: 
  
× Despite the survival of patients affected by hematological malignancies being improved 
in the last years by chemotherapy, a significant amount of patients still relapse.  
× Treatment is limited by toxicity and is constrained by the plateau of efficacy, while the 
pipeline of new chemotherapeutic drugs is running short.  
Proposed solutions: 
  
PERSONAL TERAPHY BASED ON BIOMARKERS 
9Detect polymorphisms associated with cell toxicity to develop 
personalized therapies according to the patient genotype to avoid toxicity. 
 
GENE THERAPY AND IMMUNOTHERAPY 
9T cells with Chimeric Antigen Receptors (CARs) can eradicate leukemic cells 
and perform a CD19-specific immune response in blood and bone marrow, 
showing a complete remission in the majority of patients. 
P-gp activity 
Chemotherapeutic drugs 
released from blood vessel 
P-glycoprotein 
pumps drugs out
Prognosis 
P-gp expression 
P-gp activity 
P-gp amplification 
• Despite some conflicting results in 
clinical trials and  the interindividual 
differences between ethnic groups, the 
importance of the MDR1 gene in 
chemotherapy response is undeniable. 
These interactions 
could explain the 
variability of 
response 
Clinical relevance of C3435T variants: 
We need second-line treatments more specific and less toxic for the patient 
MDR1 encoded protein 
